### SATURDAY, 17 AUGUST 2002

07:30-09:00 Breakfast (Dining Room)

**09:00-10:30** ■ **ISPE Finance Committee Luncheon** (Cedar)

11:00-16:00 ISPE Board of Directors Meeting (Cedar)

**19:00-21:30 Board Dinner** (By Invitation Only)

### SUNDAY, 18 AUGUST 2002

07:30-09:00 Breakfast (Dining Room)

09:30-10:45 ISPE Committee Meetings

Open to ISPE Members

Data Privacy Committee (Wardlaw A)

Membership & Public Relations Committee (Wardlaw B)

10:45-12:00 ISPE Committee Meetings

Open to ISPE Members

Bylaws & Policy Committee (Wardlaw A) Public Policy Committee (Wardlaw B)

**10:00-17:30 Registration** (James Watt Lounge)

#### 13:30-18:00 ■ PRE-ICPE EDUCATIONAL SESSIONS

## [A] INTRODUCTION TO PHARMACOEPIDEMIOLOGY (Lecture 4)

Jacques LeLorier, Confounding by indication Judith Jones, Cohort studies Sean Hennessy, Case-control studies Nicolas Moore, Pharmacovigilence

## [B] ADVANCED TOPICS IN PHARMACOEPIDEMIOLOGY (James Watt)

Stephen Evans, Missing data & sampling Wayne Ray, Automated databases: beyond the basics Alexander M. Walker, Propensity scores Ken Rothman, Is matching desirable in casecontrol studies?

15:30-16:30 Meeting, National Drug Utilization Research Groups (Cedar)

16:30-17:30 EURODurg General Assembly (Cedar)

**18:00-18:45** ■ Council Meetings

Academic Council (Wardlaw A) Industry Council (Wardlaw B) Government Council (Carnegie)

19:00-22:30 • WELCOME RECEPTION & CEILIDH (Hall)

Cash Bar

### **MONDAY, 19 AUGUST 2002**

06:00-08:00 Exhibitor Set-up/Open (Hall)

07:00-08:00 Poster Set-up (Session A) (Hall)

**07:00-17:00** ■ **Registration** (James Watt Lounge)

■ Speaker Ready Room (James Watt Centre II Office)

5

刀

D

07:30-09:00 Breakfast (Dining Room)

#### 08:30-10:00 ■ OPENING SESSION (James Watt)

#### Welcome

Thomas M MacDonald, Chair, 2002 Scientific Program Committee Roland T Jung, Chief Scientist for Scotland

#### **Presidential Address**

Jacques LeLorier, President, ISPE

#### **Keynote Address**

Alasdair Breckenridge

For the good of the patient: risks and benefits of medicines

10:00-10:30 Refreshment Break/Viewing of Posters & Exhibits (Hall)

#### 10:30-12:15 ■ CONCURRENT SESSIONS

## [A] SYMPOSIUM: PHARMACOECONOMICS IS NOTHING WITHOUT PHARMACOEPIDEMIOLOGY (James Watt)

Moderator:

Peter Davey

Panelists:

**David Henry,** Integrating evidence based medicine and pharmacoeconomics

**Maarten Postma**, Using Modeling to extend the results of clinical trials

**Andrew Walker,** Rigorous methods for incorporating value judgements into analysis of decision making

### [B] SYMPOSIUM: PHARMACOGENETICS (Lecture 4)

Moderator:

Munir Pirmohamed,

Panelists:

**Roland Wolf**, Research developments and practical applications in pharmacogenetics.

**Diederick E Grobbee,** Methodological issues in pharmacogenetics

ACE-ID and APOE Gene-Drug Interactions in Statin Therapy [26 & 35]

Anke Hilse Maitland-van der Zee (The Netherlands) Recipient of the 2002 Edlavitch Award

MONDAY,	19 AUGUST 2002 (Continued)  Potential Interaction between Acenocoumarol and Diclofenac, Naproxen and Ibuprofen and the Role of CYP2C9 Genotype [162]  Karen N van Dijk, Arian W Plat, Alieke AC van Dijk, Margriet Piersma-Wichers, Jennita Slomp, Lolkje TW de Jong-van den Berg, Jacobus RBJ Brouwers (The Netherlands)	15:00 15:15	<ul> <li>Implementation of a Computer Monitoring System for Detection of Adverse Drug Reactions by Laboratory Signals [362]         Manfred Criegee-Rieck, Antje Neubert, Harald Dormann, Tobias Egger, Arnim Geise, Eckhardt G Hahn, Kay Brune (Germany)     </li> <li>Influence of Backgrounds in Proportional Analysis [358] Victor V Gogolak, Ralph Edwards</li> </ul>
-	Subunit of Protein Phosphatase-1 (PPP1R3A) Is Associated with Lipid Levels and Cardiovascular Risk in Type II Diabetics in Tayside, Scotland [405] Alexander Doney, Bettina Fischer, Douglas Boyle, Andrew Morris, Patricia Cohen, David Frew, Colin	15:30	■ Data Mining: A Pharmacovigilance Tool for the Evaluation of Drug Interactions in the Post-Marketing Setting [383]  June S Almenoff, William H DuMouchel, Xionghu Yang, Allen L Kindman, David M Fram
	Palmer (United Kingdom)  Lunch (Dining Room)  Posters/Exhibits (Hall)  EURODurg Executive Committee Luncheon (Cedar) (By Invitation Only)	15:45	<ul> <li>Understanding Quantitative Signal Detection</li> <li>Methods in Spontaneously Reported Data [443]</li> <li>Andrew J Bate, Marie Lindquist, Ivor Ralph Edwards, Roland Orre (Sweden)</li> <li>[B] THERE OUGHT TO BE A LAW (Lecture 3)</li> </ul>
12:30-13:30 Open to ISPE Members	ISPE Committee Meetings/Lunch Publications Committee (Carnegie A) Development Committee (Carnegie B)	15:30	Moderators:  **Miles Braun & Rizwan Ahmed**  Ensuring Public Confidence in Vaccine Safety: Some
13:30-14:30 Open to all participants	<ul> <li>ISPE Annual Meeting of Members (James Watt)</li> <li>Annual Reports</li> <li>Awards Ceremony (ISPE)</li> <li>Distinguished Service Award: Hugh Tilson</li> <li>Student Awards</li> </ul>	14:45	Lessons from Enron and Other Public Fiascos [467]  Robert T Chen  ■ The Public's Obligations and Rights with Regard To Providing Data for Research [442]
	Edlavitch Award (Best Student Abstract):  Anke Maitland-van der Zee  2nd Best Student Abstract: David Spiro  3rd Best Student Abstract: Joelle Erkens  Best Student Methods Abstract: Maarten ten Berg  Best Student Drug Utilization Abstract: Willeke Kasje  • ISPE-PDS Prize	15:00	Ingunn Björnsdóttir, Janine Morgall Traulsen (Iceland)  Use of Electronic Medical Records in Family Physicians' Offices for Research: Privacy Concerns of Patients [446]  Donald J Willison, Karim K Keshavjee, Kalpana Nair, Anne M Holbrook, Charlie Goldsmith, Sue Troyan (Canada)
14:30-16:00 <b>•</b>	(15 minute oral abstract presentations)  A] METHODS IN PHARMACOVIGILANCE (Lecture 4)	15:15	A Consent-Based Stroke Registry: If You Build It, Will They Come? [448] Donald J Willison, Pierrot Peladeau, Frank L Silver (Canada)
14:30	Moderators:  Karen Wilcock & Inke Neutel  Communication with Patients Increases Capture of Etanercept Post-Marketing Adverse Events [440]	15:30	Drug Prices Comparison for the Reimbursable Medicines among Some East European Countries [190] Jan Komrska, Sasha Spasic, Jane Arsov, Bistra Angelovska, Guenka Petrova (Bulgaria)
44.45	Diana F Sabath, Wayne J Wallis, Thy P Do, Tom W Brethauer, John Goodleaf, Joan Holman, Daniel J Burge, Dawn Viveash	15:45	Do Doctors Rely on Pharmaceutical Industry Funding To Attend Conferences and Do They Perceive That This Creates a Bias in Their Drug
14:45	A Replication of the Weber Effect Using Post- Marketing Adverse Event Reports Submitted to the		Selection? - Results of a Questionnaire Survey to Edinburgh Doctors [143]  Philip Butledge David Crookes Brian McKinstry

SRS and AERS [186]

Nicole R Crawford, James P Wilson

Philip Rutledge, David Crookes, Brian McKinstry,

Simon RJ Maxwell (United Kingdom)

MONDAY	r, 19 AUGUST 2002 (Continued)	15:00	i	Use of Fluorquinolones Is Associated with a
	[C] GASTROENTEROLOGY (James Watt)			Reduced Risk of Coronary Heart Disease in  Diabetes Mellitus Type 2 Patients [13]  Joëlle A Erkens, Olaf H Klungel, Ron MC Herings,
	Moderators: Nicolas Moore & Jesper Hallas			Ronald P Stolk, José A Spoelstra, Diederick E Grobbee, Hubert GM Leufkens (The Netherlands)
14:30	■ The Risks of Upper Gastrointestinal Haemorrhage (UGIH) in Users of Meloxicam, Cyclooxygenase-2 (COX-2) Specific Inhibitors and Other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) [30]  Thomas M MacDonald, Daniel A Pettitt, Jay L	15:15		Pharmaceutical Content and Regimen of Hormone Replacement Therapy and Risk of Breast Cancer [296] Diane S Allen, Corinne S de Vries, Richard DT Farmer (United Kingdom)
	Goldstein, Tom A Burke, Sean Z Zhao, Steve V Morant (United Kingdom)	15:30		Hormone Replacement Therapy and Risk of Acute Myocardial Infarction [314]
14:45	<ul> <li>Declining Hospitalization and Mortality Rates from Peptic Ulcer Disease in the 1990s: Correlation with Sales of NSAIDs and Acid Suppression</li> </ul>			Susan E Bromley, Corinne S de Vries, Richard DT Farmer (United Kingdom)
	Medications [31]  James D Lewis, Warren B Bilker, Colleen Brensinger, John T Farrar, Brian L Strom	15:45		Antihypertensive Drug Therapy and the Risk of Lower Extremity Amputations in Type 2 Diabetes Mellitus Patients [11] Joëlle A Erkens, Olaf H Klungel, Ronald P Stolk,
15:00	The Risk of Esophageal Obstruction Associated with an Anti-Allergy Medication (Claritin-D 24 Hour)® [260]			José A Spoelstra, Diederick E Grobbee, Hubert GM Leufkens (The Netherlands)
	Bharati Manda, Deborah Shatin, David Graham, Carol Drinkard		[E]	DISEASE EPIDEMIOLOGY (Lecture 1)  Moderator:
15:15	<ul> <li>A Swedish Case Control Network of Drug Induced Morbidity - Acute Pancreatitis [138]</li> </ul>			Ken Rothman
	Kerstin B Blomgren, Anders Sundström, Gunnar Steineck, Sven Genell, Svante Sjöstedt, Bengt E Wiholm (Sweden)	14:30	Ī	Cardiovascular Comorbidity in the US Elderly Population with Renal and Glucose Metabolism Impairment: The Third National Health and Nutrition Examination Survey [116]
15:30	■ Irritable Bowel Syndrome and Medical Resource Use [112]  Eric Van Ganse, Michel Dapoigny, François Dyard,			Cristina Varas-Lorenzo, Ana M Rueda de Castro, Andrew Maguire, Montserrat Miret, Carles Blanch (Spain)
	Jean Charles Grimaud, Philippe Guyot (France)	14:45		Prevalence of Glucose Metabolism abnormalities and Cardiovascular Comorbidity in the US Elderly.
15:45	Risk Factors for Hospitalized Complications of Constipation: A Case-Control Study [262]  Alexander M Walker, Rhonda L Bohn, Clorinda M Cali, Suzanne F Cook, Bruce E Sands			The Third National Health and Nutrition Examination Survey (1998-1994) [140] Cristina Varas-Lorenzo, Ana M Rueda de Castro, Andrew Maguire, Montserrat Miret, Carles Blanch
	[D] HORMONES OUT OF CONTROL (Lecture 4)			(Spain)
	Moderator:  Jean-Pierre Gregorie	15:00		Risks Associated with Concomitant Respiratory  Disease in Diabetes [373]  Irene V Farquhar, Kent H Summers
14:30	Tibolone and Endometrial Cancer: A Nested Case-Control Study in the United Kingdom [422]  Corinne S de Vries, Susan E Bromley, Timothy J  Williams, Hilary Thomas, Richard DT Farmer  (United Kingdom)	15:15	•	Epidemiology of Respiratory Syncytial Virus- Related Illness in the United States: An Analysis of National Databases [36] L Clark Paramore, Vincent Ciuryla, Gabrielle
14:45	Risk of Edema in Diabetic Patients Treated with Thiazolidinediones [451] Odile Sheehy, Jacques LeLorier, Jean-Louis Chiasson (Canada)			Ciesla, Zhiyuan Liu

7

Z

MONDA	Υ, '	19 AUGUST 2002 (Continued)	17:45	<ul> <li>Adverse Drug Reactions Associated with Hospitalisations in South Australia: Trends over 13</li> </ul>
15:30	•	The Occurrence of Colonic Ischemia, Complications of Constipation, and Bowel Surgery		Years [74] Elizabeth R Roughead, Susan J Semple (Australia)
		in Relation to Irritable Bowel Syndrome [63]  J Alexander Cole, Suzanne F Cook, Anuli N Ajene, David P Miller, Alexander M Walker		[B] GLOBAL PHARMACOEPIDEMIOLOGY AND ANTI-INFECTIVES (Lecture 2)
15:45		Incidence of Acute Myocardial Infarction in Women in the UK: Secular Trends and the Association with		Moderators:  Byung Joo Park & Samuel Lesko
		Menopause [313] Susan E Bromley, Corinne S de Vries, Richard DT Farmer (United Kingdom)	16:30	Antibacterial Use and Resistance in a Large Teaching Hospital in Tehran, Iran [270] Faranak Ansari, Zohreh Rostami, S Mansor Razavi (United Kingdom)
16:00-16:30		Refreshment Break/Viewing of Posters & Exhibits (Hall)	16:45	■ Antibiotic Use Profile at Pediatric Clinics in Two
		, ,	10.45	Transitional Countries [289]
16:30-18:00		CONCURRENT SESSIONS		Goran Palcevski, Svetlana Ratchina, Vesna Rosovic-
		(15 minute oral abstract presentations)		Bazijanac, L Averchenkova, Vladimir Ahel (Croatia)
	[A	SPONTANEOUS REPORTS/ PHARMACOVIGILANCE (Lecture 3)	17:00	<ul><li>Self-Purchasing of Antibiotics by Russian Townspeople [471]</li></ul>
		Moderator: Valerie Simmons		L. S. Stratchounski, I. V. Andreeva, S. A. Ratchina, D. V. Galkin, N. A. Petrotchenkova, A. A. Demin, V. B. Kuzin, S. T. Kusnetsova, R. Y. Likhatcheva, S. V. Nederada, E. A. Ottabbara, A. S. Belikov, I. A.
16:30		Evaluation of the Clozaril Patient Monitoring Service (CPMS) in the Prevention of Clozaril/Leponex		Nedogoda, E. A. Ortenberg, A. S. Belikov, I. A. Toropova (Russian Federation)
		Induced White Blood Cell Toxicity [386] Alejandro Arana, Javier Cid Ruzafa, Ana M Rueda de Castro, Barbara A Warner, Des O'Sullivan (Spain)	17:15	Utilization of Antimicrobials in Rijeka (Croatia) [215] Vera Vlahovic-Palcevski, Vesna Rosovic-Bazijanac (Croatia)
16:45		The Association of Suicidal Behaviour with	17:30	<ul> <li>Epidemiology and Economy of Antibiotics Usage during Hospital Pneumonia Management in a</li> </ul>
		Selective Serotonin Reuptake Inhibitors (SSRIs).  Treatment or Condition? [231]  Cheryl Key (United Kingdom)		Region of Belarus [376]  Maksim Nikolay Mily, Sergey Alexander Golubev, Vladimir Yeugen Lugovoy, Gennadiy Gennadiy
17:00		Drug Safety Issues Related to Etanercept and		Voronov (Belarus)
		Infliximab: An Analysis Based on WHO/UMC Safety Database [83] Sean Z Zhao, Matthew W Reynolds	17:45	<ul> <li>Quality Predictors of Traditional Drugs Produced in Thailand [42]</li> </ul>
47.45		•		Arthorn Riewpaiboon, Rungravi Temsiririkkul, Malyn Chulasiri (Thailand)
17:15		Safety Profile of Rofecoxib as Used in General Practice in England: Results of a Prescription-		, ,
		Event Monitoring Study [121]		[C] MULTIPLE DRUG CLASSES (Lecture 1)
		Deborah Layton, Jayne Riley, Lynda V Wilton, Saad AW Shakir (United Kingdom)		Moderator:  Judith Jones
17:30		Signal Generation in Prescription Event	16:30	Drugs Associated with a Protective Effect on Non-
		Monitoring: Investigation of a Possible Signal of		Hodgkin's Lymphoma [176]
		Colitis during Rofecoxib Treatment [102]  Emma L Heeley, Deborah Layton, Saad A Shakir  (United Kingdom)		Annette B Beiderbeck, Elizabeth A Holly, Miriam CJM Sturkenboom, Jan-Willem W Coebergh, Bruno HCh Stricker, Hubert GM Leufkens (The Natherlands)

(United Kingdom)

HCh Stricker, Hubert GM Leufkens (The Netherlands)

MONDAY	<b>/</b> , ·	19 AUGUST 2002 (Continued)	17:15	÷	Concomitant Use of Sildenafil and Nitrates and
16:45	•	Folic Acid and Oral Cleft: A Case-Control Study in the United Kingdom [423] Corinne S de Vries, Man Chie Chow, Richard TD Farmer, Lolkje TW de Jong-van den Berg (United			Risk of Ischemic Events [302]  Patrick C Souverein, Toine CG Egberts, Eric JH  Meuleman, John Urquhart, Hubert GM Leufkens  (The Netherlands)
		Kingdom)	17:30		Descriptive Epidemiology of Early-Onset Adverse Effects of Cancer Chemotherapy [156]
17:00	•	Overanticoagulation Associated with Combined Use of Antibacterial Drugs and Coumarin Anticoagulants [9] Loes E Visser, Fernie JA Penning-van Beest, AA Harrie Kasbergen, Peter AGM De Smet, Arnold G			Sean Hennessy, Carol A Carozzone, Mark G Weiner, Gene A Gibson, Alice Livshits, Warren B Bilker, Erin McMenamin, M Anne Blackwood- Chirchir, Jeffrey H Silber
		Vulto, Albert Hofman, Bruno HCh Stricker (The Netherlands)	17:45	•	Safety and Efficacy of Ondansetron Following Exposure during Pregnancy:A Prospective Comparative Study [67]
17:15		Drugs Associated with Increased Risk of Non- Hodgkin's Lymphoma [180]			Adrienne Einarson, Kiran Chandra, Maltepe Caroline, Navois Yvette, Koren Gideon (Canada)
		Annette B Beiderbeck, Elizabeth A Holly, Miriam CJM Sturkenboom, Jan-Willem W Coebergh,		[E]	PROVOCATIVE METHODS (Lecture 4)
		Bruno HCh Stricker, Hubert GM Leufkens (The Netherlands)			Moderator:  Alexander M. Walker
17:30	•	Adverse Drug Events Caused by Medication Errors in Medical Inpatients [46] Beat Hardmeier, Suzanne Braunschweig, Marzia Cavallaro, Malgorzata Roos, Peter J Meier, Karin Fattinger (Switzerland)	16:30	١	Improved Comorbidity Adjustment in Epidemiologic Studies Using Medicare Claims Data [305] Sebastian Schneeweiss, Pilip S Wang, Jerry Avorn, Robert J Glynn
17:45	•	A Post-Marketing Cohort Study of Leflunomide and Other DMARDs: A Comparative Risk Analysis [225] William L Holden, Juhaeri Juhaeri, Wanju Dai	16:45	١	Adjustment Using the Propensity of Adherence: Theory, Simulation and Practical Application [429] Jixian Wang, Li Wei, Thomas M MacDonald (United Kingdom)
	[D	CASE CONTROL & COHORT STUDIES (James Watt)	17:00		A Practical Method of Anonymising and De- Identifying Medical Records for Research [417]
		Moderator: <i>Wayne Ray</i>			Philip Thompson, Frank M Sullivan, John Parkinson, Thomas M MacDonald (United Kingdom)
16:30		The Relative and Population Attributable Risk of Non- RTA Vertebral and Non-Vertebral Fracture in Patients Taking Oral and/or Inhaled Corticosteroids [244]	17:30	١	Using Record Linkage in Combination with Clinical Trials as a Resource for Pharmacoepidemiology [94]  Ian Ford, Alex D McMahon (United Kingdom)
		Peter T Donnan, Gillian Libby, Anne C Boyter, Phillip Thompson (United Kingdom)	17:45	•	Assessment of a Formula for Converting Odds Ratios To Effect Sizes: Depression Scale Outcomes
16:45		Hetastarch and Bleeding Complications after Coronary Artery Surgery [397] Jerry Avorn, Minalkumar Patel, Raisa Levin, Robert			as a Model [219]  Maarten J ten Berg, Michiel EH Hemels, Thomas  RE Einarson (The Netherlands & Canada)
		J Glynn, Wolfgang C Winkelmayer	19:00-22:30		EVENING AT DYNAMIC EARTH
17:00	•	Factors Associated with Allograft Rejection among Renal Transplant Patients in the U.S. [108] Donnie P Funch, Hnin Hnin Ko, Diana Grigsby, Jacqueline Travasso, Alexander M Walker			Admission by ticket only. Ticket includes dinner, transportation and admission. Buses depart Heriot-Watt at 19:30. (Cash bar)

9

Z

### **TUESDAY, 20 AUGUST 2002**

### Joint ISPE-EURODurg Day

07:00-08:00 Poster Set-up (Session B) (Hall)

Exhibits Open (Hall)

7:00-08:30 CERTs BREAKFAST ROUNDTABLE UPDATE – 2002 (Carnegie)

Open to all participants

The US Centers for Education and Research in Therapeutics (CERTs) ... a Roundtable [459] Hugh H Tilson, Lynn Bosco, Brian Strom, Wayne Ray

**07:00-17:00 Registration** (James Watt Lounge)

■ Speaker Ready Room (James Watt Centre II Office)

07:30-09:00 Breakfast (Dining Room)

08:30-10:15 ■ PLENARY SESSION (James Watt)

## BRINGING EPIDEMIOLOGY INTO DRUG UTILIZATION RESEARCH

Moderators:

Jacques LeLorier, President, ISPE Robert Vander Stichele, President Elect, EURODurg Panelists:

Jerry Avorn, Moving beyond drug utilization data to drug appropriateness data

**Jesper Hellas,** Individual-based drug utilization statistics. How to characterize drug use from data on individual drug dispensing

**Keith Beard,** Drug use patterns: who decides and how?

**David Henry,** Assessing appropriateness of prescribing with quality indicators in drug utilization research

10:15-10:45 Refreshment Break/Viewing of Posters & Exhibits (Hall)

#### 10: 45-12:45 ■ CONCURRENT SESSIONS

[A] SYMPOSIUM: THE EMPOWERMENT OF PHARMACOGENOMICS BY PHARMACOEPIDEMIOLOGY [372] (Lecture 4)

Moderators:

Abraham G Hartzema, M. Lee Morse

## [B] SYMPOSIUM: IMPACT OF DRUG SAFETY SCARES ON PHYSICIANS (James Watt)

Moderators:

Stephen Evans, Alice White

#### Panelists:

David Purdie, Hormone Replacement Therapy James O Drife, Oral Contraceptives David Henry, NSAIDs David Salisbury, MMR

**12:45-14:30 Lunch** (Dining Room)

Posters/Exhibits (Hall)

**■ EURODurg Poster Walk** (Hall)

Student Council/Lunch (Wardlaw)

13:00-14:00 2003 ICPE Scientific Program Committee Luncheon
Open to
ISPE Members

Carnegie)

14:30-16:00 CONCURRENT SESSIONS

(15 minute oral abstract presentations)

#### [A] VARIOUS TOPICS IN DRUG UTILIZATION (Lecture 1)

Moderator:

Frank May

14:30 Evaluation of the MedMalDE To Assess Medication Management Deficiencies in the Elderly Living in the Community [197]

Denise L Orwig, Nicole J Brandt, Ann L Gruber-Baldini

14:45 Changes of Lipid Profiles after Vitamin E
Supplementation: Comparison with Controls with
out Any Drug Use -Results of the German Federal
Health Survey- [54]

Hans-Ulrich W Melchert, Yong Du, Hildtraud Knopf, Ellen Pabel, Wulf Thierfelder (Germany)

15:00 Epoetin Alfa: Drug Utilization Study [259]

Katerina Mamzoridi, Aliki Tsakalou, Eleni Doulianaki (Greece)

15:15 Medication Management Services: Alleviating Adverse Drug Reactions [87]

Andrew L Gilbert, John D Barratt, Elizabeth E Roughead (Australia)

15:30 Medication Use in Community-Dwelling Seniors:

Baseline Results from Canadian Randomized Trial
[298]

Michelle Howard, Janusz Kaczorowski, Connie Sellors, Lisa Dolovich, John Sellors (Canada)

15:45 Lack of Discernable Effects of Retrospective Drug
Utilization Review Programs on the Frequency of
Presumptive Drug Therapy Problems [194]

Sean Hennessy, Warren B Bilker, Colleen Brensinger, Brian L Strom

10

U,

=

11

Ш

S

				THE PARTY OF THE MINANT
TUESDAY	y, 20 AUGUST 2002 (Continued)	15:00	٠	Respiratory Events in Patients Receiving Inhaled Zanamivir [98]
1	[B] BUGGING THE BUGS: KNOW YOUR ANTI- INFECTIVES (Lecture 3)  Moderator:			Jeanne E Loughlin, Tanya D Alfredson, Anuli N Ajene, J A Cole, Daniel M Rosenberg, Suzanne F Cook, Alexander M Walker
14:30	Jacques LeLorier  Antimicrobial Use and Primary Idiopathic Intussusception: A Case-Control Study [119] David M Spiro, Donald H Arnold, Fabio Barbone	15:15	•	Severe Local Reactions Following Booster Doses of DTaP Vaccines in the U.S.: A Signal from the Vaccine Adverse Event Reporting System [325]  Vitali Pool, Robert Pless, Robert T Chen
14:45	Determinants of Colonization with Antibiotic Resistant Escherichia Coli in Unselected Patients Attending General Practitioners in Germany [208] Til Stürmer, Andrea Erb, Cüneyt Gündogan, Reinhard Marre, Hans-Peter Zeitler, Hermann Brenner (Germany)	15:30	•	Drug-Induced Agranulocytosis and Thrombocytopenia: A Review of 20 Years' Experience in a Spontaneous Reporting Scheme [151] Katharina Hartmann, Christian Eggenberger, Max Kuhn (Switzerland)
15:00	Prevalence and Determinants of Pharyngeal Colonization with Antibiotic Resistant Haemophilus Parainfluenzae among Unselected Patients of General Practitioners in Germany [212] Til Stürmer, Andrea Erb, Susanne Lietzau, Marina	15:45	ID1	Investigation of a Cluster of Cellulitis Following Smallpox Vaccination [369] Christine Casey, Gina Mootrey, Vitali Pool, Robert Pless, Young Hur, Robert Chen  FOLLOWING THE GUIDELINES: DRUG UTILIZATION
	Hoewner, Reinhard Marre, Hermann Brenner (Germany)		[-]	IN CARDIOVASCULAR MEDICINE (Lecture 2) Moderator:
15:15	Health Outcomes among Patients Receiving Tamiflu [293] Cheryl Enger, Beth Nordstrom, Bharat Thakrar, Susan Sacks, Ken Rothman	14:30	٠	Robert Vander Stichele  Treatment of Cardiovascular Risk Factors in Type 2  Diabetic Patients - Who Is Not Getting Optimal  Treatment? [301]  Petra Denig, Willeke N Kasje, Flora M Haaijer-
15:30	The Effect of Zanamivir Treatment on Influenza Complications [97]  J Alexander Cole, Jeanne E Loughlin, Anuli N Ajene, Daniel Rosenberg, Suzanne F Cook, Alexander M Walker	14:45	٠	Ruskamp (The Netherlands)  Assessment of Left Ventricular Function as a Basis for Starting Treatment with ACE Inhibitors after an Acute Myocardial Infarction [131]  Åsmund Reikvam, Elena Kvan, Knud Landmark,
	Therapy-Treatment Modifications and Outcomes [241]  Leanne Beers, Vincent Lo Re, Jay Kostman, Debra  Leonard, Robert Gross	15:00	٠	Ivar Aursnes, INFARM Study Investigators (Norway)  A Survey of Secondary Prevention of Coronary Heart Disease in Ravenna, Italy [256] Fausto Marchetta, Ezio Degli Esposti, Stefania Saragoni, Giorgia Valpiani, Leona Bassein,
	[C] SCANNING FOR SIGNALS (Lecture 4)  Moderator:  Wanju Dai			Stefano Buda (Italy)
14:30	Practical Use of Automated Databases for Signal Clarification [394] Rhonda L Bohn, Drew G Levy, Juhaeri Juhaeri, Wanju Dai	15:15	i	Incidence and Determinants of CK and Liverfunction Measurements in Patients Using Statins [165] Jeroen J Derijks, Toine CG Egberts (The Netherlands)
14:45	Descriptive Case-Series Analysis of Bell's Palsy Cases in the Vaccine Adverse Event Reporting System (VAERS) [398] Weigong Zhou, Vitali Pool, Robert P Pless, Robert T Chen	15:30		Current Treatment for Chronic Heart Failure in General Practice. Is an Intervention To Improve Prescribing Really Necessary? [300] Willeke N Kasje, Petra Denig, Flora M Haaijer- Ruskamp (The Netherlands)

		ILOUIMIII
TUESDA	AY, 20 AUGUST 2002 (Continued)	[A] APPLYING METHODS (Lecture 2)
15:45	■ Trends in the Prescribing for Heart Failure in General Practice from 1996 to 2000: Do Changes in Prescribing Reflect the Current Evidence? [217] Lisa G Pont, Miriam JCM Sturkenboom, Wiek H van Gilst, Flora M Haaijer-Ruskamp (The Netherlands)	Moderators:  Mari-Ann Walander and William Holden  16:30 Validity of Hospital Discharge ICD-Codes for Identifying Patients with Hyponatraemia [58]  Kris LL Movig, Hubert GM Leufkens, Albert W
	[E] THE HIGHS & LOWS IN CNS DRUG UTILIZATION (James Watt)  Moderators:  Thomas Einarson & Flora Haaijer-Ruskamp	Lenderink, Antoine CG Egberts (The Netherlands)  16:45  Use of the Case-Crossover Design To Study Prolonged Drug Exposures and Insidious Outcomes [85] Philip S Wang, Sebastian Schneeweiss, Robert J
14:30	Are Organizational Characteristics Associated with Decreased Use of Selective Serotonin Reuptake Inhibitors (SSRIs) for the Management of Depression in US Nursing Homes? [76] Kate L Lapane, Carmel M Hughes	17:00 Selection Bias in Observational Studies of Lipid Lowering Drugs [396] Robert J Glynn, Sebastian Schneeweiss, Philip S Wang, Raia Levin, Jerry Avorn
14:45	■ Early Discontinuation and Long-Term Therapy in New SSRI Users [331]  Welmoed EE Meijer, Eibert R Heerdink, Willem A Nolen, Hubert GM Leufkens (The Netherlands)	17:15 The Design and Conduct of Cancer Registries (Cohorts) for New Drugs [120]  Gerald A Faich
15:00	■ Methods To Identify Treatment-Resistant  Depression in a Canadian Claims Database [381]  John S Hopkins, Alicia W Gilsenan, Beth H Sherrill,  Patricia K Corey-Lisle, Christopher J Longo, Joel  Raskin	17:30 Linking Registry Data on Severe Skin Reactions with Patient Data from Computerized Medical Practices: Experience of a Pilot Study [220] Maja Mockenhaupt, Juergen Schlingmann, Detlef Schroeder-Bernhardi, Erwin Schoepf (Germany)
15:15	Antidepressant Use in People with Diabetes [130] Ross A Lawrenson, John Williams (United Kingdom)	17:45 Outpatient Prescriptions in the Emergency Department: Concordance between Patients' Charts and Medication Scripts [84]
15:30	Selective Prescribing of Zyban: Comparison of Baseline Risks for Subsequent Adverse Events between Zyban Users and All GP Patients in the UK Mediplus Data [157] Leo J Russo, William C Maier	Anick Bérard, Polly E Bijur, E John Gallagher  [B] IT IS NOT JUST IN YOUR MIND (Lecture 1)  Moderator:  Corrine de Vries
15:45	<ul> <li>Pharmacological Treatment for Attention-Deficit</li> <li>Disorder with/without Hyperactivity among</li> <li>Children Aged 18 Years and Younger in the United</li> <li>States, 1996-1999 [391]</li> <li>Tongtong Wang, Boji Huang, Kenneth A</li> <li>Bachmann, Donald B White</li> </ul>	16:30 The Association between Acute Pancreatitis and Psychotropic Medication [347]  Ingo A Eland, Anders S Sundström, Miriam CJM Sturkenboom, Bruno HCh Stricker, Michael JS Langman, Bengt-Erik Wiholm (The Netherlands)
16:00-16:30	■ Refreshment Break/Viewing of Posters & Exhibits (Hall)	16:45 Less Switching after Initial Start with Atypical Antipsychotics [211] Gerard WK Hugenholtz, Eibert R Heerdink, Willem A Nolen, Hubert GM Leufkens (The Netherlands)
16:30-18:00	<ul> <li>CONCURRENT SESSIONS         <ul> <li>(15 minute oral abstract presentations)</li> </ul> </li> </ul>	17:00 Risk of Sudden Cardiac Death among Users of Anti- Psychotic Medication [308] Sabine MJM Straus, Gysele S Bleumink, Jeanne P Dieleman, Geert W't Jong, Bruno HCh Stricker

Dieleman, Geert W't Jong, Bruno HCh Stricker, Miriam CJM Sturkenboom (The Netherlands)

16:45

### TUESDAY, 20 AUGUST 2002 (Continued)

17:15 Total Mortality of Nerve/Sleeping Drug Users in a General Middle-Aged Population [453]

Svetlana Skurtveit, Aage Tverdal (Norway)

17:30 Urinary Incontinence Induced by Serotonergic Antidepressants [56]

Kris LL Movig, Hubert GM Leufkens, Svedlana V Belitser, Bertil W Lenderink, Antoine CG Egberts (The Netherlands)

17:45 Risk of Diabetes and Hyperlipidemia among Atypical Antipsychotics Ambulatory Users [72]

Jocelyne Moisan, Jean-Pierre Grégoire, Michel Gaudet, Dan Cooper (Canada)

#### [C] WOMEN'S HEALTH (Lecture 3)

Moderators:

Elizabeth Andrews & Lolkje T.W. de Jong van den Berg

16:30 Are Hormone Replacement Therapy (HRT) Users 
"Healthier" Than Non-Users? Results from the 
Canadian Multicentre Osteoporosis Study (CaMos)

[426]

Anick Bérard, Claudie Berger, David Hanley, Susan A Kirkland, Timothy Murray, Jerilynn C Prior, the CaMos Research Group

Pregnancy and Post-Marketing Medication Safety:
 Strategies for Pregnancy Detection in Automated
 Medical Records [385]

Janet R Hardy, Theodore R Holford, Gillian C Hall, Michael B Bracken

17:00 Venous Thromboembolism in Women with Androgenic Skin Conditions or PCOS Using Cyproterone Acetate

+ Ethinyloestradiol: A Nested Case-Control Study [291] Helen E Seaman, Corinne S de Vries, Richard DT Farmer (United Kingdom)

## **Ingenix Epidemiology and Safety Research**

Ingenix is the global integrated pharmaceutical services division of UnitedHealth Group, providing scientifically based solutions for the pharmaceutical, biotechnology and medical device industries to help accelerate the development and adoption of health products. The Epidemiology and Safety Research division has a world-renowned reputation for providing information about the safety and effectiveness of prescription and nonprescription therapies. Using the vast data resources of Ingenix, our experienced epidemiologists, analysts, and researchers provide high-quality





information capable of meeting the expectations of scientific reviewers and regulators.

As an industry leader in drug safety research, Ingenix offers expertise in the design, conduct and analysis of:

- Large-scale retrospective safety evaluations
- Prospective safety monitoring (pharmacovigilance)
- Treatment patterns and product utilization
- Descriptive studies about the natural occurrence of disease

### Ingenix - Epidemiology and Safety Research

Riverside Center, Suite 3-120, 275 Grove Street, Auburndale, MA 02466 USA Tel: 617-244-1200 • Fax: 617-244-9669 • www.ingenix.com

Please visit us at our booth for more information.

13

⊂ m

J

TUESE	OAY, 20 AUGUST 2002 (Continued)	[E] WHEEZLES & SNEEZLES: DRUG USE IN ASTHMA & INFECTIONS (James Watt)
17:15	<ul> <li>Incidence Rates of Colonic Ischemia, Serious Complications of Constipation, and Bowel Surgery in Relation to Lotronex Use [316]</li> </ul>	Moderator:  Debra Rowett
	David P Miller, Suzanne F Cooke, Bruce Sands, Tanya Alfredson, Anuli Ajene, Alexander M Walker	16:30 Use of Inhaled Corticosteroids Following an Emergency Department Visit for Asthma: Determinants of Use among Children and
17:30	■ The Risk of Liver Disease Associated with Cyproterone Acetate + Ethinyloestradiol: A Nested Case-Control Study in Women with Androgenic Skin Conditions or PCOS [292]	Adolescents [312]  Lucie Blais, Sylvie Lévesque, Marie-France Beauchesne (Canada)
	Helen E Seaman, Corinne S de Vries, Richard DT Farmer (United Kingdom)	16:45 Persistence on Asthma Anti-Inflammatory Agents in Quebec Adult Patients [295]  Marc Dorais, Lucie Blais, Jacques LeLorier (Canada)
17:45	■ Women with Ischaemic Heart Disease Receive Less	
	Secondary Preventive Therapy but More Anxiolytics Than Men [128] David Williams, Kathleen Bennett, John Feely (Ireland)	17:00 ■ Guideline Adherence for the Treatment of Asthma in General Practice Is Associated with a Higher Quality of Life [175]
	[D] THE RISK OF DRUG USE (Lecture 4)	Lisa G Pont, Thys van der Molen, Ger T vander Werf, Flora M Haaijer-Ruskamp (The Netherlands)
	Moderator:  Jacques LeLorier	17:15 Affecting the Use of Antibiotics in General Practice through Outreach Visits [135]
16:30	Conversion from Intravenous to Oral Medications: Assessment of a Computerized Intervention [425] Michael A Fischer, Daniel H Solomon, Jerry Avorn	Keld Vaegter, Jens P Kampmann, Jens Kirkegaard, Kim Kristensen, Kurt Svaerdsudd (Denmark)
		17:30 Evaluation of Sepsis Management and Intravenous
16:45	Quality Indicators on Prescription Data for Evaluating Appropriateness of Drug Use [436] Alberto Vaccheri, Elisabetta Poluzzi, Davide Resi, Chiara Silvani, Domenico Motola, Nicola Montanaro (Italy)	to Oral Antibiotic Switch Protocols [132]  Ronald A Seaton, Catherine M McLaughlin, Neena  Bodasing, Carl Fenelon, Jonathan Fox (United  Kingdom)
	memanare (naily)	17:45 Use of Antibiotics at Hospitals in Stockholm - A
17:00	<ul> <li>Investigation into Causes of Preventable Drug- Related Admissions to a Medical Admissions Unit [145]</li> </ul>	Benchmarking Project Using Internet: www.janus info.org [370] Ulf Bergman, Helena Risinggård (Sweden)
	Rachel L Howard, Anthony J Avery, Paul D Howard, Malcolm Partridge (United Kingdom)	COLOR OF COCIAL EVENTS (Optional**)
4= 4=		6:30-20:30 SOCIAL EVENTS (Optional**)
17:15	Non-Steroidal Anti-Inflammatory Drug Use: Impact of Risk Factors for Gastropathy on Prescribing	[A] MILITARY TATTOO
	Practices [274] Yola Moride, Thierry Ducruet, Matthew W	OR
	Reynolds, Sean Z Zhao (Canada)	[B] EVENING AT THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH
17:30	Prescribing for Heart Failure in General Practice: The Relationship between Physician Knowledge and Prescribing Quality [257] Lisa G Pont, Wiek H van Gilst, Dirk JA Lok, Hans Kragten, Flora M Haaijer-Ruskamp (The Netherlands)	**Separate registration required- includes dinner, admission & transportation. Dinner will be served in the Dining Room. Buses will depart Heriot-Wattt at 19:15.

17:45

Patterns of Topical Glaucoma Drug Utilization [356]
Michelle Houde, Anne-Marie Castilloux, Jacques

LeLorier (Canada)

	[B]	NSAIDS-Selecting Your Pain (James Watt)
Hall)		Moderators:  Anick Berard and Ineke Neutel
yer) s Watt Centre II Office)		Nonsteroidal Anti-Inflammatory Drug Exposure and the Relative Risk of Colorectal Cancer, Gastrointestinal and Renal Adverse Events [10] Timothy E Niecko, Jeffrey A Kotzan, Joseph T
		DiPiro, Bradley C Martin
NS 08:15 entations)	5	GI Risk Factors in Patients Prescribed COX-2 Agents and NSAIDs [317] Daniel H Solomon, Raisa Levin, Jerry Avorn
00:00	_	40. Other and Theorem American Three Months of Falling
08:30		18 Stay on Therapy during Three Months of Follow Up of Patients on Selective COX-2 Inhibitors and Other Nonselective NSAIDs in an Elderly Population [187]
d Functional Status or Myocardial neweiss, Eric Knight,		Elham Rahme, Michael A Marentette, Youssef Toubouti, Sheldon X Kong, Jacques LeLorier (Canada)
08:45	5	Start of NSAIDs Increases the Risk of Renal Dysfunction in Users of ACE Inhibitors [263]
m Mortality in ite Myocardial lherence [321]		Marcel L Bouvy, Eibert R Heerdink, Arno W Hoes, Hubert GM Leufkens (The Netherlands)
e Y Wong, Thomas M 09:00		Comparison of Gastrointestinal Events Reported for Rofecoxib and Meloxicam Using Prescription- Event Monitoring (PEM) Data in England [281]
ohort Study of the Infarction [395] Walker, Paige L		Deborah Layton, Emma Heeley, Kerry Hughes, Saad AW Shakir (United Kingdom)
rdon M Saperia 09:15	5	Gastrointestinal Complications Associated with
pitalization for		Rofecoxib/Celecoxib and Other Nonselective NSAIDs: Analysis of the Government Claims
es, Hubert GM		Database in Quebec, Canada [188]  Elham Rahme, Michael A Marentette, Youssef  Toubouti, Sheldon X Kong, Jacques LeLorier (Canada)
1.1112	[C]	SCOTCH BLEND (Lecture 2)
e innibitors are Risk of Acute		Moderator:  Keith Beard
icker, Michael JS (The Netherlands)		Discontinuation/Persistency of Drug Therapy Using Administrative Databases: A Systematic Review of the Literature [160] Thy P Do, Eric S Johnson, Essy Mozaffari
_	_	· ·
han, James K Liao, boys, Charles M Blatt		Meta-Analysis of Placebo Rates in a Defined Population of Patients with Major Depressive Disorder [101] Pieter Stolk, Maarten J ten Berg, Michiel E Hemels, Thomas R Einarson (The Netherlands & Canada)
	Watt Centre II Office)  IS O8:15 O8:15 O8:15 O8:16 O8:16 O8:16 O8:16 O8:17 O8:17 O8:18 O8:18 O8:18 O8:18 O8:18 O8:18 O8:18 O8:19 O8:18 O8:19 O8:	Watt Centre II Office)  IS Watt Centre II Office)  IS IS INTICUTIONAL Status IT Myocardial Interpretation of the Infarction [395] Walker, Paige L Idon M Saperia Inticution of the Infarction of Infar

15

Ш

Z

Ш

S

WEDNES	DAY, 21 AUGUST 2002 (Continued)	09:15	■ The Use of ∞– Blockers and 5–∞ Reductase
08:30	Quantifying the Interaction between Aspirin and Angiotensin-Converting-Enzyme Inhibitors: Resolving Discrepancies Using a Meta-Analysis [ Bahi Takkouche, Mahyar Etminan, Paco Camano Paula Rochon (Canada)	-	Inhibitors Decreases the Risk of Prostate Surgery for Patients Diagnosed with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia [233]  Katia MC Verhamme, Jeanne P Dieleman, Gysele S Bleumink, Johan van der Lei, Bruno HCh Stricker, Miriam CJM Sturkenboom (The Netherlands)
08:45	Celecoxib and Cardiovascular Thromboses- Methodological Issues in Pooling Trial Data [95] A Faich, Robert W Makuch, William White		[E] MONEY CHANGES EVERYTHING (Lecture 1)  Moderators:  Hugh Tilson & Peter Davey
09:00	Program on Incidence of Varicella Disease in an HMO Population [47]  John P Mullooly, Julie E Maher, Lois Drew	08:00	Incidence, Treatment and Outcomes of Complicated Intra-Abdominal Infections [361] Miriam C Sturkenboom, Wim Goettsch, Bas In't Veld, Gino Picelli, Ron MC Herings (Italy)
09:15	The Detection of Preventable Adverse Drug Even among Ambulatory Geriatric Patients [129] Jerry H Gurwitz, Terry Field, Leslie Harrold, Jeffn Rothschild, Kristin Debellis, Andrew Seger, Cynth Cadoret, Leslie Fish, Lawrence Garber, Jackie Cernieux, David Bates	08:15	■ Health Care Resource Utilization during One-Year Treatment with Long-Acting Risperidone [213]  Adriane R Leal, Devos Emmanuel, Bernard  Bernard, Duchesne Inge, Mehnert Angelika (Belgium)
[D]	WATERFALL (Lecture 3) Moderator:  JW van der Velden	08:30	Net Healthcare Savings from Reference Drug Pricing for Angiotensin-Converting Enzyme Inhibitors [307] Sebastian Schneeweiss, Colin Dormuth, Paul Grootendorst, Malcolm Maclure
08:00	A Study of the Incidence of Fractures in Men Receiving Medical Therapy for Lower Urinary Tra Symptoms (LUTS) [360] Richard DT Farmer, John W Logie, Nicola Christ (United Kingdom)		The Impact of Low Dose Aspirin Prescribing on Upper Gastrointestinal Toxicity, Renal Toxicity and Healthcare Resource Utilisation [389]  Thomas M MacDonald, Steve V Morant, Alex D McMahon, John GF Cleland, Peter G Davey
08:15	Too Short Course of Trimethoprim or Nitrofuranto May Lead to an Increased Number of Treatment Failures of Urinary Tract Infections [107] Wim G Goettsch, Ron MC Herings (The Netherland	09:00	(United Kingdom)  Is It Cost-Effective To Improve Compliance with
08:30	An Analysis of Cardiac Dysrhythmia in Overactiv Bladder Patients Using Tolterodine and Other	,	Lipid-Lowering Therapy? [268]  Joshua S Benner, David A Ganz, Milton C Weinstein, Peter J Neumann, Robert J Glynn, Jerry Avorn
	Overactive Bladder (OAB) Medications [82]  Matthew W Reynolds, Sean Z Zhao, John-Kenne Billingsley, Scott C Henderson	<b>09:15</b>	Noncompliance with Statin Therapy: Lost Clinical Benefits and Implications for Cost-Effectiveness [267] Joshua S Benner, David A Ganz, Milton C Weinstein, Peter J Neumann, Robert J Glynn, Jerry Avorn
08:45	Burden of Illness of Urinary Incontinence for the Italian NHS: An Exploratory Approach Using Administrative Data [469]  Salvatore Mannino, Silvio Cavuto, Lorenzo	09:30-10:00	
	Colonna, Nicola Groth, Marco Salmoiraghi, Andre Belloli (Italy)	10:00-11:30	■ CONCURRENT SESSIONS  Symposium - (James Watt)
09:00	Utilization of Macrolides and the Development of Streptococcus Pyogenes Resistance to Erythromycin [92]  Karel Urbanek, Milan Kolar (Czech Republic)		[A] Drug Related Problems in the Elderly-Epidemiology, Interventions, and Biostatistical Considerations [27] Joseph T Hanlon, Michael D Murray, Duncan R

Petty, Carl F Pieper

Karel Urbanek, Milan Kolar (Czech Republic)

### WEDNESDAY, 21 AUGUST 2002 (Continued)

- WORKSHOPS [B] [F]
- [B] Benefit Risk Analysis: A Proposal Using Epidemiologic Methods [299] (Wardlaw A) William L Holden, Juhaeri Juhaeri, Wanju Dai
- [C] Pharmacoepidemiology: Can It Help Evidence-Based Practice? [339] (Wardlaw B) Junius Gonzales, Paul Stang
- [D] Measuring the Appropriateness of Drug Use [236] (Physics 113)

Lynn M Weekes, Flora M Haaijer, Ingrid S Sketris (Australia)

[E] Risk Management: What Are We Driving, Where Are We Going, and How Will We Know When We Get There? [384] (Physics 114)

> Elizabeth B Andrews, Allen A Mitchell, Peter Honig, Suzanne F Cook, Alicia Gilsenan

[F] What's New in GPRD and What Impact Will This Have for Researchers? [379] (Physics 115) Susan Eaton, Carlos Martinez, Tim Williams, Lisa McQuay

**11:30-13:30 Lunch** (Dining Room)

- Posters/Exhibits (Hall)
- ISPE Board of Directors Luncheon (Carnegie)
- 13:30-15:00 CONCURRENT SESSIONS Symposium (James Watt)
  - [A] Approaches to Postmarketing Surveillance for Teratogens in the US: Challenges and Progress [276]

Stanley A Edlavitch, Dianne L Kennedy, Elizabeth B Andrews, Allen A Mitchell, Janet D Cragan, Jose F Cordero

# **RTI Health Solutions**

- 40 Years of Research Experience
- + Broad-Based Technical Expertise
- + Multidisciplinary Teams
- + Client-Focused Infrastructure
- = The Perfect Solution for Your Needs!

- Epidemiology
- Medication Risk Management Programs
- Large Database Studies (GPRD, NHANES, Medicare, Saskatchewan)
- Statistical Analysis
- Data Collection/Data Management
- Health Economics
- Patient-Reported Outcomes
- Product Valuation Analysis
- Market Research

Contact Elizabeth Andrews at 1-919-541-5819 or visit our web site at www.rtihs.org

[MEASURES THAT COUNT]

17

Ш

Z

7

**)** 

### 13:30-15:00 ■ WORKSHOPS [B]- [G]

[B] Turning Risks into Opportunities [3] (Wardlaw A)

JW van der Velden, Ross L. Lawrenson, Annette
Stemhagen (The Netherlands, UK, USA)

[C] What Is a Signal? [416] (Wardlaw B)

Miles Braun, Begaud Bernard

[D] Pitfalls in the Disproportionality Approach for the Identification of Alerts from Spontaneous Reporting Systems [452] (Physics 113)

Nicholas D Moore, Gillian Hall, Ron Mann, Miriam Sturkenboom, Rajaa Lagnaoui (France)

[E] Application of Epidemiology in Pre-Approval Drug Development [404] (Physics 114)

Robert S Brody, Ken Rothman, Mary-Lou Skrovan, Stephen Evans, Paul Seligman

[F] The Broader Issues in Drug Safety Case Report Analysis [444] (Physics 115) Victor V Gogolak, Ralph Edwards

[G] Prescription-Event Monitoring: Review of the Methodology, Recent Developments and Adaptation to Different Countries [287] (School of Mgt G20) Saad AW Shakir, Lynda V Wilton, David M Coulter, Kiyoshi Kubota (United Kingdom)

#### 15:00-16:00 ■ INVITED PLENARY SESSION (James Watt)

Moderator:

Jacques LeLorier

Plenary Speaker:

Hershel Jick

Principles & Methods in Pharmacoepidemiology Research

#### **16:00-17:30** ■ **HOT TOPIC SESSION** (James Watt)

COX2-Selective Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Disease [336]

Moderator:

Wayne A Ray

Panelists:

Thomas M MacDonald Daniel H Solomon David Graham Jerry Avorn

#### 17:30-17:45 THE FINAL WORD (James Watt)

Sean Hennessy, Chair, 2003 Scientific Progam Committee

17:45 Adjournment of the 18th ICPE



# Department of Epidemiology Blue Bell, Pennsylvania

The Department of Epidemiology resides within Merck Research Laboratories (MRL). The Department is structured around therapeutic categories with representatives from the department involved throughout product development to provide significant input to clinical trial programs and to Outcomes Research initiatives. Research involves several general areas: basic epidemiology and disease natural history to support new drug development; outcomes research; selection, development, validation, and psychometric evaluation of patient-reported outcome measures for use in clinical trials; training and standardization of rater scales and other outcome measures; epidemiologic support for health economic studies and model development; post-marketing safety surveillance of vaccines; secondary analysis of internal and external datasets; and pharmacoepidemiologic studies. Newer areas of interest include genetic epidemiology.

Research typically involves grant-funded collaboration with external investigators. In addition, the department conducts research using numerous internal and publicly available databases. Research also involves collaboration with other MRL departments in providing epidemiologic information to support trial design, sample size estimation, endpoint definition, and interpretation of clinical trial results. Additional collaborative research involves design of effectiveness studies and use of epidemiologic information in health economic models. Epidemiology also provides consultation to Marketing, Regulatory, and Public Affairs.

Professional staff members in the Epidemiology Department regularly publish in peer-reviewed journals and present at leading scientific conferences. Last year, members of the department published roughly 40 research articles or book chapters as well as 46 abstracts. In addition, members gave over 40 presentations at scientific meetings.

Interested candidates with strong qualifications in genetic epidemiology should send a resume along with a cover letter indicating salary requirements to HR Manager – Drew Lewis/Epidemiology, Merck & Co., Inc, BL1-1, P O Box 4, West Point, PA 19486-0004. An Equal Opportunity Employer – M/F/D/V (Resumes from recruiting agencies are not accepted.)

D N E S D A Y